3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
4
Neoplasms
3
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms, Unknown Primary
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Cyclophosphamide
31
fludarabine
28
Whole-Body Irradiation
18
Mycophenolic Acid
18
venetoclax
14
Tacrolimus
14
fludarabine phosphate
13
Standard of Care
13
Specimen Handling
10
Practice Guidelines as Topic
10
Melphalan
10
Busulfan
10
Sirolimus
9
Thiotepa
8
Interviews as Topic
8
Azacitidine
8
Educational Status
7
trametinib
6
Surveys and Questionnaires
6
Methods
6
Mesna
6
Biopsy
6
thymoglobulin
5
Rituximab
5
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Early Intervention, Educational
5
Behavior Therapy
5
Antilymphocyte Serum
5
Peripheral Blood Stem Cell Transplantation
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
entrectinib
×
1 year
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled